Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Two cases of patients with multiple myeloma and kidney failure successfully underwent CAR T-cell therapy using ciltacabtagene autoleucel.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.